Celularity Equity Warrants Exp 16 July 2026 CELUW:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
0.0246quote price arrow up+0.0034 (+15.7702%)
Volume
1,666
52 week range
0.00 - 0.16
Loading...
  • Open0.0237
  • Day High0.0246
  • Day Low0.0234
  • Prev Close0.0212
  • 52 Week High0.16
  • 52 Week High Date06/29/23
  • 52 Week Low0.00
  • 52 Week Low Date12/18/23

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.0237
  • Day High0.0246
  • Day Low0.0234
  • Prev Close0.0212
  • 52 Week High0.16
  • 52 Week High Date06/29/23
  • 52 Week Low0.00
  • 52 Week Low Date12/18/23
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Celularity Equity Warrants Exp 16 July 2026

 

Profile

MORE
Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells...
Robert Hariri M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
David Beers
Chief Financial Officer
John Haines
Senior Executive Vice President, Chief Administrative Officer, General Manager
Address
170 Park Ave
Florham Park, NJ
07932
United States